Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials

被引:64
作者
Bottomley, A
Efficace, F
Thomas, R
Vanvoorden, V
Ahmedzai, SH
机构
[1] European Org Res & Treatment Canc Data Ctr, Qual Life Unit, B-1200 Brussels, Belgium
[2] Royal Hallamshire Hosp, Palliat Med Unit, Sheffield S10 2JF, S Yorkshire, England
[3] Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
关键词
D O I
10.1200/JCO.2003.01.203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Non-small-cell lung cancer (NSCLC), a leading cause of cancer-related deaths in both developed and developing countries, heavily impacts patient health-related quality of life (HRQOL). Although recent research has found many positive and significant steps in randomized controlled trials (RCTs) in which HRQOL has been used as an outcome, questions remain regarding methodologic quality and impact value of HRQOL outcome assessments in some RCTs. To date, no detailed systematic review exists of HRQOL methodology in NSCLC RCTs. Methods: A systematic review using Cochrane methodology evaluated HRQOL components in RCTs. Identified studies were evaluated independently by three reviewers on a broad set of predetermined criteria. Results: Twenty-nine published RCTs (NSCLC patient samples total, N = 8,445) with an HRQOL component were identified. Although most trials exhibited good-quality research and useful HRQOL and clinical data, the weaknesses identified in some trials include such common limitations as no clear hypothesis, lack of a clear approach to missing data and data analysis, and limited presentation of results. Conclusion: Although it is clear that HRQOL is an important end point in NSCLC RCTs because the information helps to influence treatment recommendations, the identified weaknesses in conducting HRQOL measurement in NSCLC RCTs and the reporting of results need to be addressed.
引用
收藏
页码:2982 / 2992
页数:11
相关论文
共 61 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].
Anderson, H. ;
Hopwood, P. ;
Stephens, R. J. ;
Thatcher, N. ;
Cottier, B. ;
Nicholson, M. ;
Milroy, R. ;
Maughan, T. S. ;
Falk, S. J. ;
Bond, M. G. ;
Burt, P. A. ;
Connolly, C. K. ;
McIllmurray, M. B. ;
Carmichael, J. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453
[3]   Patient-reported short-term and long-term physical and psychologic symptoms: Results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer [J].
Bailey, AJ ;
Parmar, MKB ;
Stephens, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3082-3093
[4]   A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer [J].
Ball, D ;
Smith, J ;
Bishop, J ;
Olver, I ;
Davis, S ;
OBrien, P ;
Bernshaw, D ;
Ryan, G ;
Millward, M .
BRITISH JOURNAL OF CANCER, 1997, 75 (05) :690-697
[5]   Uneasy alliance - Clinical investigators and the pharmaceutical industry [J].
Bodenheimer, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1539-1544
[6]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[7]   Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? [J].
Bottomley, A ;
Thomas, R ;
van Steen, K ;
Flechtner, H ;
Djulbegovic, B .
LANCET ONCOLOGY, 2002, 3 (03) :145-153
[8]   Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo lung cancer study group [J].
Buccheri, G ;
Ferrigno, D .
LUNG CANCER, 1997, 18 (01) :57-70
[9]  
BUCCHERI GF, 1989, CANCER, V63, P428, DOI 10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO
[10]  
2-V